Aberdeen Group
KRYS icon

Aberdeen Group’s Krystal Biotech KRYS Stock Holding History

Aberdeen Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.9M Buy
44,893
+19,752
+79% +$6.84M 0.02% 509
2026
Q2 		$9.34M Sell
25,141
-5,014
-17% -$1.5M 0.01% 611
2026
Q1 		$7.79M Sell
30,155
-9,205
-23% -$2.45M 0.01% 629
2025
Q4 		$9.7M Sell
39,360
-20,012
-34% -$4.21M 0.02% 616
2025
Q3 		$10.5M Sell
59,372
-49,146
-45% -$7.36M 0.02% 594
2025
Q2 		$14.9M Buy
108,518
+71,217
+191% +$10.5M 0.03% 495
2025
Q1 		$6.73M Sell
37,301
-19,732
-35% -$3.32M 0.01% 645
2024
Q4 		$8.93M Buy
57,033
+13,979
+32% +$2.48M 0.02% 532
2024
Q3 		$7.84M Sell
43,054
-318
-0.7% -$61.3K 0.01% 566
2024
Q2 		$7.96M Buy
43,372
+4,348
+11% +$730K 0.02% 550
2024
Q1 		$6.94M Buy
+39,024
New +$5.42M 0.01% 608

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Aberdeen Group's KRYS Position: Q3 2026 in Review

Aberdeen Group increased its Krystal Biotech (KRYS) stake by 79% in Q3 2026, buying an estimated $6.84M and bringing the position to 44,893 shares worth $14.9M. The position accounts for 0.02% of the portfolio, ranked #509.

Aberdeen Group first reported a position in KRYS in Q1 2024 and has held it in 11 quarters since. 353 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • Aberdeen Group held 44,893 shares of Krystal Biotech worth $14.9M as of Q3 2026.
  • Aberdeen Group bought 19,752 Krystal Biotech shares in Q3 2026, an estimated $6.84M.
  • Krystal Biotech made up 0.02% of Aberdeen Group's portfolio in Q3 2026, its #509 holding.
  • Aberdeen Group first reported a position in Krystal Biotech in Q1 2024 and has held it in 11 quarters since.
  • 353 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on Aberdeen Group's 13F filing for Q3 2026, filed 6 Nov 2026.